Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders

Neuropsychopharmacology

Volumn 21, Issue , 1999, Pages 91S-98S

  Blier, Pierre ^a   de Montigny, Claude ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antidepressant; Electroconvulsive shocks; Hippocampus; Lithium; Orbito frontal cortex; Pindolol

Indexed keywords

5 METHOXYTRYPTAMINE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DOPAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRONIAZID; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; PAROXETINE; PINDOLOL; POSTSYNAPTIC RECEPTOR; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; LIMBIC CORTEX; NONHUMAN; OBSESSION; PANIC; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC TRANSMISSION; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MODELS, NEUROLOGICAL; NEURONS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; RECEPTORS, SEROTONIN; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 0032819493     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00036-6     Document Type: Article

References (58)

1. Artigas F, Perez V, Alvarez E (1994): Pindolol induces a rapid improvement of depressed patients with serotonin reuptake inhibitors. Arch Gen Psychiat 51:248-251
2. Baxter LR Jr. (1995): Neuroimaging studies of human anxiety disorders. In Bloom FE, Kupfer D (eds), Psychopharma-cology: The Fourth Generation of Progress. New York, Raven, pp 1287-1300
3. Bei'que J-C, de Montigny C, Blier P, Debonnel, G (1998): Blockade of the 5-hydroxytryptamine and norepinephrine uptake by venlafaxine: Comparative study with paroxetine and desipramine. Brit J Pharmacol 125:526-532
4. Bergqvist PBF, Bouchard C, Blier P (1999): Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. BiolPsychiat 45:164-174
5. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS (1997): Effect of pindolol in hastening response to fluox-etine in the treatment of major depression: A doubleblind, placebo-controlled trial. Am J Psychiat 154:37-43
6. Blier P, Bergeron R (1995): Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J ClinPsychopharmacol 15:217-222
7. Blier P and Bergeron, R (1997): Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: Are they related? IntClinPsychophar-macol 12:21-28
8. Blier P, Bouchard C (1994): Modulation of 5-HT release in the guinea pig brain following long-term administration of antidepressant drugs. Br J Pharmacol 113:485-495
9. Blier P, de Montigny C (1983): Electrophysiological studies on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3:1270-1278
10. Blier P, de Montigny C (1985): Serotonergic but not norad-renergic neurons in rat CNS adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 16:949-955
11. Blier P, de Montigny C (1987): Modifications of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse 1:470-480
12. Blier P, de Montigny C (1994): Current advances and trends in the treatment of depression. Trends PharmacolSci 15:220-226
13. Blier P, de Montigny C, Azzaro AJ (1986): Modification of serotonergic and noradrenergic neurotransmission by repeated administration of monoamine oxidase inhibitors: Electrophysiological studies in the rat CNS. J Phar-macolExpTher 227:987-994
14. Blier P, Bergeron R, de Montigny C (1997): Selective activa-tion of postsynaptic 5-HT1A receptors produces a rapid antidepressant response. Neuropsychopharmacology 16:333-338
15. Bloch RG, Dooneief AS, Buchberg AS, Spellman S (1954): The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann Int Med 40:881-900
16. Bordet R, Thomas P, Dupuis B (1998): Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiat 155:1346-1351
17. Bradwejn J, Koszycki D, Shriqui C (1991): Enhanced sensitiv-ity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiat 48:603-610
18. Bradwejn J, Koszycki D (1994): Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiat 151:261-263
19. Chaput Y, de Montigny C, Blier P (1986): Effect of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 333:342-348
20. Chaput Y, de Montigny C, Blier P (1991): Presynaptic and postsynaptic modifications of the serotonin system by long-term antidepressant treatments: Electrophysiologi-cal studies in the rat brain. Neuropsychopharmacology 5:219-229
21. Charney DS, Heninger GR, Breier A (1984): Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiat 43:1155-1161
22. Coppen A (1967): The biochemistry of affective disorders. Brit J Psychiat 113:1237-1264
23. deMontigny C (1984): Electroconvulsive treatments enhance responsiveness of forebrain neurons to serotonin. J PharmacolExpTher 228:230-234
24. deMontigny C (1989): Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: Preliminary findings. Arch Gen Psychiat 46:511-517
25. deMontigny C and Aghajanian GK (1978): Tricyclic antide-pressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303-1306
26. deMontigny C, Grunberg F, Mayer A, Deschenes JP (1981): Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiat 138:252-256
27. Dinan TG, Barry S (1989): A comparison of electroconvulsive therapy with a combined lithium and tricyclic combina-tion among depressed tricyclic nonresponders. Acta PsychiatrScand 80:97-100
28. El Mansari M, Bouchard C, Blier P (1995): Alteration of serotonin release in the guinea pig orbitofrontal cortex: rele-vance to the treatment of obsessive compulsive disorder. Neuropsychopharmacology 13:117-127
29. El Mansari M, Blier P (1997): Effect of a prolonged paroxetine treatment on the responsiveness of postsynaptic 5-HT receptors in the rat orbitofrontal cortex. Neurosci (Abst) 23:974
30. Fernandez CE, Lopez-Ibor JJ (1967): Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. ActasLusoEspNeurolPsiquiatrCienc 26:119
31. Goodman WK, Ward H, Kablinger A, Murphy T (1997): Flu-voxamine in the treatment of obsessive-compulsive disorder and related conditions. J ClinPsychiat 58:32-49
32. Haddjeri N, Blier P, de Montigny C (1998): Long-term antidepressant treatments result in a tonic activation of fore-brain 5-HT1A receptors. J Neurosci 18:10150-10156
33. Insel TR (1992): Toward a neuroanatomy of obsessive-com-pulsive disorder. Arch Gen Psychiat 49:739-744
34. Jenike MA (1993): Obsessive-compulsive disorder: Efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 29:487-499
35. Klein DF (1964): Delineation of two drug-response anxiety syndromes. Psychopharmacologia 5:397-408
36. Kuhn R (1958): The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiat 115:459-464
37. Leonard HL, Swedo S, Rapoport JL, Coffey M, Cheslow D (1988): Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: A double-blind cross-over comparison. Psychopharma-col Bull 24:93-95
38. McCall RB and Aghajanian GK (1979): Serotonergic facilita-tion of facial motoneuron excitation. Brain Res 169:11-27
39. Menkes DB, Aghajanian GK, McCall RB (1980): Chronic antidepressant treatment enhances a-adrenergic and serotonergic responses in the facial nucleus. Life Sci 27:45-55
40. Montgomery SA (1980): Clomipramine in obsessional neuro-sis: A placebo- controlled trial. Pharm Med 1:189-192
41. Montgomery SA (1994): Pharmacological treatment of obsessive-compulsive disorder. In Hollander E, Zohar J, Marazziti D, Olivier B (eds), Current Insights in Obsessive Disorder. New York, Wiley, pp 215-226
42. Moret C, Briley M (1990): Serotonin autoreceptorsubsensi-tivity and antidepressant activity. Eur J Pharmacol 180:351-356
43. Paudice P, Raiteri M (1991): Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 103:1790-1794
44. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997): Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594-1597
45. Robinson DS, Rickels K, Feighner J, Fabre LF, Jr. Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME (1990): Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J ClinPsychopharmacol 10:67S-76S
46. Romero L, Bel N, Artigas F, de Montigny C, Blier P (1996): Effect of pindolol at pre- and postsynaptic 5-HT1A recep-tors: In vivo microdialysis electrophysiological studies in the rat brain. Neuropsychopharmacol 15:349-360
47. Rouillon F, Gorwood P (1998): The use of lithium to augment antidepressant medication. J ClinPsychiat 59:32-41
48. Rueter L, de Montigny C, Blier P (1998): Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrener-gic systems. J PharmacolExpTher 285:404-412
49. Stahl SM, Kaiser L, Roeschen J, KeppelHesselink JM, Orazem J (1998): Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: Support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsy-chopharmacol 1:11-18
50. Szabo ST, de Montigny C, Blier P (1999): Long-term treatment with paroxetine decreases the firing activity of locus coeruleus noradrenergic neurons. Brit J Pharmacol 126:568-571
51. Tada K, Kasamo K, Ueda N, Suzuki T, Kojima T, Ishikawa K (1999): Anxiolytic 5-hydroxytryptamine1A agonists sup-press firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats. J PharmacolExpTher 288:843-848
52. Tome MB, Isaac MT, Harte R, Holl C (1997): Paroxetine pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int ClinPsychopharmacol 12:81-89
53. vanMegen HJGM, Westenberg HGM, den Boer JA, Kahn RS (1996): Cholecystokinin in anxiety. EurNeuropsychopharmacol 6:263-280
54. West ED, Dally PJ (1959): Effects of iproniazid in depressive syndromes. Br Med J 5163:1491-1494
55. Wilkinson LO, Auerbach SB, Jacobs BL (1991): Extracellular serotonin levels change with behavioral state but not pyrogen-induced hyperthermia. J Neurosci 11:2732-2741
56. Wilcox CS, Ferguson JM, Dale JL, Heiser JF (1996): A doubleblind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 32:335-342
57. Zanardi R, Artigas F, Sforzini L, Gasperini M, Smeraldi E, Perez J (1997): How long pindolol should be associated to paroxetine to improve the antidepressant response. J ClinPsychopharmacol 17:446-450
58. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J (1998): Faster onset of fluvoxamine in combina-tion with pindolol in the treatment of delusional depression: A controlled study. J ClinPsychopharmacol 18:441-446